New triple-threat weapon needed in war between man and microbe

Mar 24, 2008
New triple-threat weapon needed in war between man and microbe
Without a breakthrough, microbial resistance might be inevitable in humanity's struggle against infectious disease, a medicinal chemist reports. Above is a color-enhanced scanning electron micrograph showing Salmonella typhimurium (red) invading cultured human cells. Courtesy of National Institute of Allergy and Infectious Diseases of the NIH

Mankind’s age-old battle against infectious diseases stands to rage on and on, unless scientists develop a new generation of triple-action antibiotics, according to an article scheduled for the March 28 issue of ACS’ monthly Journal of Natural Products.

In the article, Lester A. Mitscher presents a “rather personalized” account of the turbulent tug-of-war between microbes and mankind, describing past tactics, lessons learned, and a cautious prediction about the road ahead.

Mitscher notes, for instance, that “miracle drugs” in the 1940s and ’50s failed to live up to expectations. Though penicillin promised an end to infections worldwide in 1941, reports of resistant bacteria appeared only a year later. “Significant clinical resistance is now known for virtually all antibiotics in medical use,” the article states. “Unfortunately, the problem is getting worse since big pharma has largely withdrawn from research directed toward new antibiotic discovery.”

The review concludes that microbial resistance is inevitable pending unforeseen breakthroughs. One involves development of new antibiotics that go beyond killing or slowing the growth of disease-causing microbes. Those new medications would contain antimutagenic ingredients that discourage bacteria from mutating into resistant forms. In addition, they would pack immunostimulants that enlist the body’s own immune defense system to fight off an infection.

“Continued close observation and exploitation of natural phenomena appear at present to be the wisest course for scientists to follow in trying to deal with this problem,” says Mitscher.

Source: ACS

Explore further: Space-tested fluid flow concept advances infectious disease diagnoses

add to favorites email to friend print save as pdf

Related Stories

First look at breast microbiota raises tantalizing questions

Mar 24, 2014

The female breast contains a unique population of microbes relative to the rest of the body, according to the first-ever study of the breast microbiome. That study sought to lay the groundwork for understanding how this bacterial ...

Chemists discover new class of antibiotics

Mar 07, 2014

(Phys.org) —A team of University of Notre Dame researchers led by Mayland Chang and Shahriar Mobashery have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) ...

Resistance shapes the discovery of new insecticides

Feb 17, 2014

Recent news around the world has focused on the dangers of antibiotic resistance. But what of another type of resistance which can also have a huge impact on the population: that to insecticides? ...

Tough life key to croc immunity

Feb 10, 2014

(Phys.org) —The immune systems of crocodiles and alligators have remained relatively unchanged for centuries despite their worldwide distribution, as revealed for the first time by University of Sydney ...

Recommended for you

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

zbarlici
not rated yet Mar 24, 2008
triple-action antibiotics? First we`d better see a quadruple-action antibiotic policy in place worldwide, aimed at ensuring proper use of antibiotics, as from what i understand there is too much abuse of antibiotic use as it is, in a sense that it is relied on too much and it is improperly used...
Soylent
not rated yet Mar 25, 2008
Currently drug companies develop drugs that can be patented and sold at a large markup to cover R&D costs and generate a profit.

Perhaps it would be better if society could put out a large bounty on drug treatments for all diseases in proportion to what curing or controling them is worth to society and only allow this bounty to be collected upon meeting specific demands for efficacy, safety and at the expense of not patenting the drug. That would allow society a good measure of control over which diseases are targeted by drug companies.

More news stories

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.

Health care site flagged in Heartbleed review

People with accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the ...